High plasma homocysteine: A risk factor for vascular disease in the elderly

Coronary Artery Disease

Volumn 9, Issue 11, 1998, Pages 725-730

  Moustapha, Ali ^a   Robinson, Killian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Elderly; Folic acid; Homocysteine; Vitamin B12; Vitamin B6

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PYRIDOXINE;

ADULT; AGED; BLOOD LEVEL; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASE; KIDNEY FAILURE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITAMIN DEFICIENCY;

EID: 0032424842     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809110-00004     Document Type: Review

References (36)

1. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Deckker Inc.; 1992. pp. 183-236. A most useful reference for all work on homocysteine and atherosclerosis until the date of publication (1992). It provides a broad outline of homocysteine biochemistry and metabolism, interrelationships with vitamin and essential enzymes and summarizes much of the earlier work on vascular disease.
2. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27:517-527.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057. A useful meta-analysis of many of the studies relating homocysteine to vascular disorders.
4. Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest 1986; 77:1482-1486.
5. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
6. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 80:1463-1469.
7. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, et al. Hyperhomocysteinemia in stroke: prevalence, cause and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22:214-221. Demonstrates the importance of homocysteine as a risk factor for stroke in the elderly and emphasizes the association between homocysteine, renal function and cofactors for homocysteine metabolism.
8. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-2698. This study involved elderly subjects from the Framingham heart study and showed a strong association between plasma homocysteine, age and lower vitamin status. The high homocysteine levels seen in this population can be attributed to low vitamin status.
9. 12, serum creatinine and multivitamin usage are the most important determinants of plasma homocysteine concentration in middle-aged and elderly randomly selected residents. The age-related increase in homocysteine may be linked to the age-related impairment of renal failure.
10. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-2830.
11. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. JAMA 1995; 274:1526-1533. This study aimed to assess the relation between established cardiovascular risk factors and plasma homocysteine. Elevated plasma homocysteine was associated with other major risk factors for cardiovascular disease, namely male sex, old age, hypertension, hypercholesterolemia and sedentary lifestyle. This study is particularly important because it is very comprehensive and involves a large number of participants (7591 men and 8585 women).
12. Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22:79-87.
13. Nordström M, Kjellström T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis 1992; 94:213-221.
14. Gartler SM, Hornug SK, Motulsky AG. Effect of chronologic age on induction of cystathionine synthase, uroporphyrinogen I synthase, and glucose-6-phosphate dehydrogenase activities in lymphocytes. Proc Natl Acad Sci USA 1981; 78:1916-1919.
15. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976; 57:1079-1082.
16. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:709-715.
17. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81:51-60.
18. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90:1-11. This article is a general review of the association between homocysteine and various forms of thrombotic diseases.
19. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-1155.
20. Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991; 13:128-136.
21. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762.
22. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kulle LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17:1947-1953.
23. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9-19.
24. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997; 277:1775-1781. This is a large multicenter case-control study that aimed to study the role of plasma homocysteine as a risk factor for vascular disease and the interaction with other risk factors. Graham and co-workers found that high homocysteine levels potentiate the cardiovascular adverse effects of smoking and diabetes.
25. Aronow WS, Ahn C, Schoenfeld MR. Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am J Cardiol 1997; 79:1432-1433.
26. Aronow WS, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. Am J Cardiol 1997; 80:1216-1218.
27. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286-291.
28. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996; 57 (suppl):S11-S17.
29. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97:138-141.
30. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98:5-7.
31. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98:24-29.
32. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelial-dependent vasodilation in humans. Circulation 1997; 95:1119-1121.
33. 6. This study is particularly important because it focuses on possible therapeutic strategies in the elderly population.
34. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Lancet 1998; 351:263.
35. 6 supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359-364.
36. Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25:176-181.